Today: 20 March 2026
Subscribe
Browse Category

TSX:4519 8 July 2025 - 28 November 2025

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

Rani Therapeutics shares traded around $1.59 on 28 November, down from the previous close of $1.62 but still well above pre-October levels. No new press releases or SEC filings were issued today. The stock’s recent surge followed a major Chugai Pharmaceutical collaboration and $60.3 million private placement. Market cap stands near $190–200 million with roughly 97.5 million shares outstanding.
28 November 2025
··
Tokyo Stock Exchange Surges to Record Highs on AI Boom – Inside the Nov 3, 2025 Rally

Japan Stocks Today: Topix Closes at Record 3,359 as Nikkei Ends at 51,063; Sony’s Upgrade Offsets SoftBank Slump, Yen Nears ¥155

Topix closed at a record 3,359.33, up 1.14%, while the Nikkei 225 rose 0.43% to 51,063.31. SoftBank fell after confirming a $5.8 billion sale of its Nvidia stake; Sony jumped on an 8% profit forecast hike. The yen weakened near ¥155 per dollar. About 78% of Prime market stocks advanced.
12 November 2025
········
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···
The State of AI: Agentic Revolution, Healthcare Breakthroughs & Global Governance / Updated: 2025, July 8th, 12:00 CET

The State of AI: Agentic Revolution, Healthcare Breakthroughs & Global Governance / Updated: 2025, July 8th, 12:00 CET

More than 777 FDA-cleared AI devices are in clinical use for medical imaging in the U.S., cutting scan times and flagging urgent cases. Microsoft's MAI-DxO system reached 85.5% diagnostic accuracy, far above doctors at 20%. The U.S. Senate rejected a 10-year moratorium on state AI regulation. Meta recruited Apple’s Ruoming Pang for its AI push, while Wimbledon 2025 adopted AI-driven line calling amid player criticism.
8 July 2025
······

Stock Market Today

  • RTX Shares See 52% Gain in Year - Is It Overvalued at $200?
    March 20, 2026, 1:45 AM EDT. RTX's share price rose 51.8% over the past year but dropped 1.4% last month, trading around $200.73. A Discounted Cash Flow (DCF) analysis values RTX at $183.11, suggesting the stock is about 9.6% overvalued based on projected free cash flows. Despite promising aerospace and defense sector positioning, valuation signals are mixed, with a 3 out of 6 score indicating both undervaluation and fair pricing factors. Investors should watch RTX closely for market shifts and updates to fundamentals that could affect its value.
Go toTop